[Prevention of fetal and neonatal transmission of the varicella-zoster virus].
Varicella occurs in 0.7 to 0.13% of pregnant women. The risk of transmission of the varicella-zoster virus to the fetus is small. The virus causes malformations (cutaneous scars and above all central nervous system anomalies). Mother-to-offspring transmission is more common during the perinatal period (20%), when mild or severe (fatal in 20% of cases) congenital varicella may occur. Prevention of transmission of the varicella-zoster virus from the mother to her fetus or neonate rests on detection of fetal varicella (antenatal ultrasonography, fetal IgM assays) and on administration of both specific anti-VZ virus immune globulins and acyclovir to the mother and neonate during the perinatal period.
Haddad
J
J
Hôpitaux Universitaires de Strasbourg, Service de Néonatalogie, Hôpital de Hautepierre, Strasbourg, France.
Gut
J P
JP
Lokiec
F
F
D000212:Acyclovir / Q000627:therapeutic use*; D002644:Chickenpox / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control* / Q000635:transmission; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D014740:Vidarabine / Q000627:therapeutic use*
D014740:Vidarabine; D000212:Acyclovir
Prévention de la transmission du virus de la varicelle et du zona au foetus et au nouveau-né.